全文获取类型
收费全文 | 14090篇 |
免费 | 797篇 |
国内免费 | 118篇 |
专业分类
耳鼻咽喉 | 184篇 |
儿科学 | 291篇 |
妇产科学 | 187篇 |
基础医学 | 2146篇 |
口腔科学 | 346篇 |
临床医学 | 1267篇 |
内科学 | 2646篇 |
皮肤病学 | 525篇 |
神经病学 | 1105篇 |
特种医学 | 627篇 |
外科学 | 2049篇 |
综合类 | 52篇 |
一般理论 | 2篇 |
预防医学 | 603篇 |
眼科学 | 371篇 |
药学 | 1318篇 |
中国医学 | 183篇 |
肿瘤学 | 1103篇 |
出版年
2023年 | 74篇 |
2022年 | 55篇 |
2021年 | 422篇 |
2020年 | 279篇 |
2019年 | 360篇 |
2018年 | 403篇 |
2017年 | 342篇 |
2016年 | 488篇 |
2015年 | 647篇 |
2014年 | 752篇 |
2013年 | 824篇 |
2012年 | 1308篇 |
2011年 | 1184篇 |
2010年 | 729篇 |
2009年 | 631篇 |
2008年 | 837篇 |
2007年 | 861篇 |
2006年 | 740篇 |
2005年 | 671篇 |
2004年 | 554篇 |
2003年 | 447篇 |
2002年 | 418篇 |
2001年 | 310篇 |
2000年 | 292篇 |
1999年 | 218篇 |
1998年 | 62篇 |
1997年 | 53篇 |
1996年 | 33篇 |
1995年 | 55篇 |
1994年 | 28篇 |
1993年 | 20篇 |
1992年 | 83篇 |
1991年 | 69篇 |
1990年 | 83篇 |
1989年 | 69篇 |
1988年 | 64篇 |
1987年 | 48篇 |
1986年 | 50篇 |
1985年 | 45篇 |
1984年 | 29篇 |
1983年 | 33篇 |
1981年 | 22篇 |
1980年 | 19篇 |
1979年 | 37篇 |
1978年 | 44篇 |
1977年 | 25篇 |
1976年 | 20篇 |
1975年 | 30篇 |
1974年 | 27篇 |
1973年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
So Young Jeon Oh Eun Kwon Jin Woo Jang Sang Yoon Kang Jin-Young Min Sung Wan Kim 《Auris, nasus, larynx》2021,48(5):1031-1034
Stickler syndrome is a genetic disorder of connective tissue. One of the major symptoms associated with this disorder is an oro-facial malformation, which may cause a submucous cleft or a complete cleft of the hard palate. A 32-year-old man diagnosed with Stickler syndrome and a submucosal cleft palate (SMCP) visited our hospital with a chief complaint of excessive daytime sleepiness. The patient was diagnosed with severe obstructive sleep apnea (OSA), and administration of a polysomnography test revealed an apnea-hypopnea index (AHI) of 30.9 events/hour (h). Auto-titrating continuous positive airway pressure was initiated to control the OSA symptoms and subsequently the patient showed some improvement. However, due to continuous velopharyngeal insufficiency symptoms, intravelar veloplasty was performed. Three months after surgery, the AHI had decreased to 12.4 events/h. Recent studies have described a greater risk for OSA in individuals with cleft palate, than in the general population. The present case demonstrates surgical success in a patient with OSA and SMCP, suggesting that palatal surgery may be considered an optional surgical treatment for OSA patients with SMCP. 相似文献
2.
3.
4.
5.
Su Yeon Jang Jeong-Yeon Seon Baik-Lin Eun Seong-Beom Koh Jin-Hong Yoo Woo Yong Lee Ho-Kee Yum Seok-Jun Yoon In-Hwan Oh Sang-Cheol Bae Sung-Goo Chang 《Journal of Korean medical science》2021,36(18)
BackgroundCoronavirus disease 2019 (COVID-19) has spread around the globe, and it is important to determine the risk factors of death in the general population. Our study aimed to determine the risk factors of death and severe illness requiring supplemental oxygen therapy based on the demographic and clinical characteristics of COVID-19 patients in Korea.MethodsIn this study, we used data provided by the Korea Disease Control and Prevention Agency (KDCA) and analyzed a total of 5,068 patients with COVID-19, excluding 19 pregnant women and 544 individuals with missing data. We performed logistic regression analysis to determine the impact of early symptoms on survival and severe disease. Logistic regression models included sex, age, number of comorbidities, symptoms on admission, blood pressure, heart rate, and body temperature as explanatory variables, and death and oxygen therapy as outcome variables.ResultsLogistic regression analyses revealed that the male sex, older age (≥ 60 years), higher number of comorbidities, presence of symptoms on admission, heart rate ≥ 120 bpm, and body temperature ≥ 37.5°C presented with higher risk of in-hospital death and oxygen therapy requirement. Conversely, rhinorrhea and headache were associated with a low risk of death and oxygen therapy requirement. The findings showed that cough, sputum, and fever were the most common symptoms on admission, while 25.3% of patients with COVID-19 were asymptomatic.ConclusionCOVID-19 patients with high-risk early symptoms on admission, such as dyspnea and altered mental status, and those without low-risk symptoms of rhinorrhea and headache should be included in priority treatment groups. 相似文献
6.
7.
Stefano Cascinu György Bodoky Kei Muro Eric Van Cutsem Sang Cheul Oh Gunnar Folprecht Sumitra Ananda Gustavo Girotto Zev A. Wainberg Maria Luisa Limon Miron Jaffer Ajani Ran Wei Astra M. Liepa Roberto Carlesi Michael Emig Atsushi Ohtsu 《The oncologist》2021,26(3):e414-e424
BackgroundIn the intent‐to‐treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent of tumor shrinkage, as well as associations with symptom palliation.Materials and MethodsTumor response was assessed with RECIST v1.1, and quality of life (QoL) was assessed with the European Organization for Research and Treatment of Cancer Quality‐of‐Life Questionnaire‐Core 30 (EORTC QLQ‐C30) v3.0. Prespecified and post hoc analyses were conducted in the ITT population, patients with measurable disease, or responders, and included best overall response (BOR), ORR, disease control rate (DCR), duration of response, time to response (TtR), change in tumor size, and associations of QoL with tumor shrinkage and BOR.ResultsIn both treatment arms, median TtR was 1.5 months. Responses were more durable in the ramucirumab versus control arm (median 4.4 vs. 2.8 months). In patients with measurable disease (78% of ITT), ORR was 36% versus 20%; DCR was 81% versus 61% in the ramucirumab versus control arms. Waterfall plots demonstrated more tumor shrinkage in the ramucirumab versus control arm. Regardless of treatment, tumor response and stable disease were associated with improved or stable QoL, with more tumor shrinkage associated with greater symptom palliation.ConclusionTreatment with ramucirumab plus paclitaxel yielded the highest ORR reported to date for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. Additional details demonstrate robustness of tumor response results. The extent of tumor shrinkage is directly associated with symptom palliation and should be considered when evaluating patient needs and treatment selection. Clinical trial identification number. .Implications for PracticeRamucirumab plus paclitaxel is a recognized standard of care as it improves survival for patients with advanced gastric or gastroesophageal junction adenocarcinoma who have been previously treated with recommended first‐line therapy. These additional data on tumor response demonstrate a positive association between tumor shrinkage and symptom palliation in a patient population that is often symptomatic. These observations included patients with nonmeasurable disease, a group of patients often underrepresented in clinical trials. This knowledge can inform treatment decisions, which align individual patient characteristics and needs with demonstrated benefits. NCT01170663相似文献
8.
9.
Morihito Okada Yoshihiro Miyata Kazuya Takamochi Yasuhiro Tsutani Shiaki Oh Kenji Suzuki 《The Journal of thoracic and cardiovascular surgery》2019,157(1):388-395
Objective
Vascular sealing with an energy vessel sealing system during lung resection may allow surgeons to treat small vessels with minimal dissection, possibly decreasing likelihood of injury. Few large prospective trials have examined the proximal sides of vessels not ligated in addition to sealing during surgery. We therefore assessed feasibility of an energy device to seal pulmonary artery and vein branches without further ligation.Methods
This prospective, preoperative registration study at 2 institutions evaluated safety of energy sealing with the LigaSure (Medtronic, Minneapolis, Minn), with no additional reinforcing material such as suture ligation, for pulmonary vessels as large as 7 mm during anatomic lung resection (cohort 1 study). A postoperative hemorrhage occurred in the 128th case, so a cohort 2 study proceeded after we changed inclusion criterion for pulmonary arteries from a maximum of 7 mm to a maximum of 5 mm.Results
In cohort 1 (n = 128) and cohort 2 (n = 200), 216 and 250 pulmonary arteries and 189 and 213 pulmonary veins, respectively, were treated with energy sealing. Overall postoperative hemorrhage rate was 0.3% (1/328 patients); however, no serious postoperative complications were associated with energy sealing among the 200 patients in cohort 2. Subsequent inspection of the torn artery stump confirmed that the bleeding in the 128th case was in an area adjacent to the sealing zone.Conclusions
Energy sealing without reinforcement allows secure treatment during lung resection of pulmonary arteries as large as 5 mm in diameter and pulmonary veins as large as 7 mm. 相似文献10.